// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Faecal microbiota composition in adult, newly diagnosed, treatment-naïve IBD patients

Krznaric - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

The gut microbiota composition and metabolic activity of HLA-B27 transgenic rats with gut inflammation resembles the dysbiotic characteristics of human inflammatory bowel disease

V Svolos - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Crohn’s disease is characterised by a fungal dysbiosis

A Frau - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

N/A

The functional exoproteome as a driver and predictor of IBD status: Proteases from bacteria influence host health

L S Osborne - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Increasing research capacity of IBD nurses across Europe—a case study of Inflammatory Bowel Disease Fatigue (IBD-F) scale translation and validation

W Czuber-Dochan - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Cognitive behavioural therapy for the management of inflammatory bowel disease-fatigue: A pilot randomised controlled trial

M Artom - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

IBDoc® self-care/point-of-care calportectin test: Early value in a district general hospital inflammatory bowel disease service

P Avery - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Audit of compliance with intravenous (IV) iron dosing and evaluation of the IV service in patients with inflammatory bowel diseases (IBD) at Antrim Area Hospital, UK

J Kearns - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Iron isomaltoside

Patients experience of advice received on the use of topical therapies in inflammatory bowel disease (IBD)

T Tyrrell - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Young adults living with inflammatory bowel disease. A thematic synthesis of patient experience

S Fourie - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

The use of intravenous (IV) ferric carboxymaltose in a paediatric IBD population

K Crook - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Ferric carboxymaltose

Nurse-led video conference (VC) clinic follow-up of IBD patients in the remote and rural setting of the Scottish Highlands

D Armour - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Developing a quality of life score for Crohn’s anal fistula (CAF-QoL)

S Adegbola - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

N/A

N/A

Patient satisfaction with brand changes of Mesalazine medications in four hospitals in the North West of England

R Campbell - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Mesalamine

A qualitative exploration into experiences of living with Crohn’s anal fistula

S Adegbola - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

N/A

N/A

Medication adherence and medication beliefs among women with inflammatory bowel disease in reproductive age

T Tsavdaroglou - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Telephone/email service provided to IBD patients by Canadian IBD nurses

U Chauhan - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Systems genomics of ulcerative colitis: combining GWAS and signalling networks for patient stratification and individualised drug targeting in ulcerative colitis

J Brooks - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

N/A

Improved endoscopic outcomes and mucosal healing of upadacitinib as an induction therapy in adults with moderately to severely active ulcerative colitis: data from the U-ACHIEVE study

W J Sandborn - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

ABT-494

A randomised, multi-centre, double-blind, placebo-controlled study of a targeted release oral cyclosporine formulation in the treatment of mild-to-moderate ulcerative colitis: efficacy results

S Bloom - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

Cyclosporine eent

Copyright © 2026. QuantiNova All rights reserved